Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia

Authors

Judith A. Boel, Department of Neurology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands.
Rob M. de Bie, Department of Neurology Amsterdam UMC Location University of Amsterdam Amsterdam The Netherlands.
Ben A. Schmand, Department of Psychology University of Amsterdam Amsterdam The Netherlands.
John C. Dalrymple-Alford, New Zealand Brain Research Institute and School of Psychology, Speech and Hearing University of Canterbury Christchurch New Zealand.
Connie Marras, Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital University of Toronto Toronto Canada.
Charles H. Adler, Arizona Study of Aging and Neurodegenerative Disorders, Mayo Clinic Arizona, Scottsdale, Arizona, USA and Banner Sun Health Research Institute Sun City Arizona USA.
Jennifer G. Goldman, Department of Physical Medicine and Rehabilitation and Neurology Shirley Ryan AbilityLab and Northwestern University Chicago Illinois USA.
Alexander I. Tröster, Department of Clinical Neuropsychology and Center for Neuromodulation Barrow Neurological Institute Phoenix Arizona USA.
David J. Burn, Institute of Neuroscience Newcastle University Newcastle upon Tyne UK.
Irene Litvan, Parkinson and Other Movement Disorder Center, Department of Neurosciences University of California San Diego California USA.
Gert J. Geurtsen, Amsterdam Neuroscience Amsterdam The Netherlands.

Document Type

Article

Abstract

BACKGROUND: The criteria for PD-MCI allow the use of global cognitive tests. Their predictive value for conversion from PD-MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown. METHODS: The MDS PD-MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD-MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD. RESULTS: PD-MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, = 0.001; HR = 4.14, = <0.001). The C-statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II. CONCLUSION: MMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD-MCI.

Publication Date

5-1-2022

Publication Title

Movement disorders clinical practice

E-ISSN

2330-1619

Volume

9

Issue

4

First Page

479

Last Page

483

PubMed ID

35582313

Digital Object Identifier (DOI)

10.1002/mdc3.13451

Recommended Citation

Boel, Judith A.; de Bie, Rob M.; Schmand, Ben A.; Dalrymple-Alford, John C.; Marras, Connie; Adler, Charles H.; Goldman, Jennifer G.; Tröster, Alexander I.; Burn, David J.; Litvan, Irene; and Geurtsen, Gert J., "Level I PD-MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia" (2022). Clinical Neuropsychology. 271.
https://scholar.barrowneuro.org/neuropsychology/271